#Latin America NGS Report

[mohitbisresearch]

The Latin America NGS market was valued at $268.04 million in 2024 and is anticipated to reach $597.20 million by 2034, witnessing a CAGR of 8.34% during the forecast period 2024-2034.

[usafphantom2]

Saab presents strategic defense solutions at LAAD

Fernando Valduga By Fernando Valduga 04/10/23 - 09:53 in LAAD, Military, Saab

Saab will present at LAAD Defence & Security 2023 highly technological defense solutions, with emphasis on the Gripen fighter and the MSHORAD anti-aircraft defense system.

Saab, a leading company in defense and security technologies, will participate in LAAD Defence & Security 2023, which will take place between April 11 and 14, in Rio de Janeiro. During the event, the company will present a broad portfolio of state-of-the-art air, land and naval solutions.

Saab maintains a partnership with the Brazilian Armed Forces and seeks to expand its strategic performance in the region, as highlighted by Marianna Silva, general director of Saab in Latin America:

"Saab has a strong history of cooperation with the Brazilian Armed Forces. In addition to the Gripen program, we can highlight our anti-aircraft defense and training and simulation solutions, and advanced information monitoring and fusion systems, used in the Integrated Border Monitoring System (SISFRON)," explains Marianna Silva. "We want to expand this strategic partnership and we are excited to present our cutting-edge solutions for Latin America," he adds.

The Gripen E multimission fighter, called F-39 Gripen by the Brazilian Air Force (FAB), will again be one of the great highlights in LAAD. The full-size replica of the hunt will be open for public visitation during the event without the need for prior scheduling. The aircraft is a symbol of the largest technology transfer program from Sweden to Brazil, with a great contribution to the development of the national defense industry. The first four fighters, of the 36 aircraft acquired by the Brazilian Air Force, are already in operation in the country.

Another great highlight of Saab in LAAD will be the low-height mobile anti-aircraft defense system (Mobile Short-Range Air Defense - MSHORAD), an anti-aircraft defense solution with a high degree of mobility to accompany mechanized and armored troops in displacement, which combines one or more RBS 70 firing units and a Giraffe 1X radar, interconnected to Saab' At the booth, Saab demonstrates the possibility of integrating an RBS70 NG shooting unit into the Brazilian Army's Armored Medium Personnel Transport Vehicle (VBTP MSR) Guarani.

Low-height mobile anti-aircraft defense system (Mobile Short-Range Air Defense - MSHORAD) in the Guarani.

The Giraffe 1X prototype will also be on display. The short-range, transportable and multi-mission three-dimensional X-band radar can be easily unfolded in various environments, from terrestrial (fixed or mobile) to naval platforms, in the Sea Giraffe 1X version, as well as stationary positions and any type of C2 structure.

The public will be able to get to know other solutions, such as Saab's ground combat systems such as the Carl-Gustaf® M4, the new generation of portable and multifunctional weaponry used in the protection of troops and combat facilities, and the NLAW, an anti-tank missile system, both used in numerous NATO member countries in their operations.

For the naval sector, the company brings advanced solutions for maritime defense, such as the Mining Countermeasures Ship (MCMV) that performs a water scan capable of detecting threats from underwater mines. The complete solution includes the use of untried autonomous vehicles to remove and disarm mines.

Ads

REPORT THIS ANNOUNCEMENT

Tags: Military AviationF-39 GripenLAADsaab

Fernando Valduga

Fernando Valduga

Aviation photographer and pilot since 1992, he has participated in several events and air operations, such as Cruzex, AirVenture, Dayton Airshow and FIDAE. He has works published in specialized aviation magazines in Brazil and abroad. Uses Canon equipment during his photographic work throughout the world of aviation.

Related news

An Embraer KC-390 flies escorted by four F-5 fighters and a FAB Gripen - Photo Sgt. Muller Marin - 7.Mar.2022

LAAD

Embraer and Saab team up to sell the KC-390 in Europe

11/04/2023 - 17:54

HELICOPTERS

Australian Chinook refuels combat tanks

04/11/2023 - 09:00

MILITARY

Turkey orders unmanned aircraft carrier TCG Anadolu

11/04/2023 - 07:00

AMCA from HAL.

MILITARY

Rolls Royce makes a great offer for India's fighter aircraft engine program

10/04/2023 - 16:00

HELICOPTERS

Chilean Air Force starts search for replacement for its Huey helicopters

10/04/2023 - 14:00

MILITARY

USAF F-16 in South Korea begins to receive APG-83 AESA radar update

10/04/2023 - 13:00

homeMain PageEditorialsINFORMATIONeventsCooperateSpecialitiesadvertiseabout

Cavok Brazil - Web Creation Tchê Digital

Commercial

Executive

Helicopters

HISTORY

Military

Brazilian Air Force

Space

Specialities

Cavok Brazil - Web Creation Tchê Digital

[snehalblog]

MENA Syringes & Cannula Market: Key Growth Drivers and Future Outlook - UnivDatos

According to a new report by UnivDatos Market Insights, The MENA Syringes & Cannula Market was valued at USD 1,505.79 million in the year 2023 and is expected to grow at a strong CAGR of around 7.29% during the forecast period. Owing to the aging population is more vulnerable to illnesses that require hospitalization and medical procedures that involve syringes and cannula. As per the United Nations Population Fund (UNFPA), in 2024, the United Arab Emirates is going through a demographic transition as the number of persons aged 60+ is expected to increase more than six-fold between 2020 - 2050 from about 311,000 (3.1% of the total population) to 2 million (19.7%). Adding to this, the increased rate of diabetes, cardiovascular diseases, and other chronic diseases led to other increased frequency of standard medical procedures. Furthermore, the use of devices like cannula for surgeries and treatments has increased as medical procedures have advanced.

Request To Download Sample of This Strategic Report - https://univdatos.com/reports/causal-ai-market?popup=report-enquiry&utm_source=LinkSJ&utm_medium=Snehal&utm_campaign=Snehal&utm_id=snehal

The report suggests that Syringes & Cannula resources in the MENA region had a significant impact on the Syringes & Cannula industry in the MENA region. Some of how this impact has been felt include:

· In April 2024: Medline announced it has entered into a definitive agreement to acquire Ecolab, Inc.'s global surgical solutions business, including the industry-leading Microtek product lines. Once closed, the acquisition will provide Medline with innovative sterile drape solutions for surgeons, patients, operating room equipment, and Ecolab’s fluid temperature management system.

· In May 2023, Pfizer and Thermo Fisher Scientific Inc. announced they have entered into a collaboration agreement to help increase local access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients in more than 30 countries across Latin America, Africa, the Middle East and Asia where advanced genomic testing has previously been limited or unavailable.

· In February 2021, the Advanced Medical Technology Association (AdvaMed) inked a MoU, entering a formal relationship with MECOMED, MEA’s medical devices, imaging, and diagnostics trade association. The collaboration facilitated information sharing between both organizations and increased the ability to strengthen this market.

· In May 2021, Medovate, a medical device manufacturer in the U.K., announced a partnership in the Middle East. The Cambridge-based specialist has teamed up with Kuwait’s Omneya Medical Co. to distribute its SAFIRA (SAFer Injection for Regional Anesthesia) device in the Gulf country.

Apart from this, in recent years, UAE has significant growth in MENA, and North Africa has enhanced the growth of the Syringes & Cannula industry:

The UAE is expected to grow with a significant CAGR during the forecast period (2024-2032). The market of syringes and cannula in UAE is consequently driven by government initiatives to enhance healthcare and construct better healthcare facilities. The current government’s investment in health under Vision 2021 has emphasized quality health facilities that depend majorly on medical disposables for the overall safe course of medical practice. For instance, in October 2022, the Ministry of Industry and Advanced Technology (MoIAT) announced the signing of a pair of MoU worth Dh 260 million (USD 7 million) between major pharmaceutical companies and medical devices companies in the United Arab Emirates. The UAE has a well-developed healthcare sector featuring modern hospitals and clinics generating demand for superior medical consumables like syringes and cannula. In addition, the UAE is one of the prominent medical tourism destinations in the region, hosting patients from all corners of the world and adding to the demand for medical devices and supplies.

Ask for Report Customization - https://univdatos.com/reports/causal-ai-market?popup=report-enquiry&utm_source=LinkSJ&utm_medium=Snehal&utm_campaign=Snehal&utm_id=snehal

Conclusion

In conclusion, Syringes & Cannula market in the MENA region is anticipated to show considerable growth in the future due to strategic healthcare investments and increasing incidences of chronic diseases. It was found that technological factors are indeed crucial, of which the move towards safer and more efficient medical device is prominent. However, one of the major issues facing the market players is the operationalization of these diverse regulatory frameworks regarding renewable energy implementation within the different countries of the MENA region. Therefore, in the future, the focus must be on long-term development and marketing, investing in innovation and compliance to capture new opportunities and maintain the scale of competitiveness in this evolving and growing healthcare market.

[skyquest-market-research]

MicroRNA Market Key Insights and Growth Opportunities, Forecast - 2031

The global microRNA (miRNA) market has gained substantial attention in recent years, driven by its expanding applications in disease diagnosis, therapeutics, and biomedical research. As per the latest insights from SkyQuest Technology, the global microRNA market is projected to reach a value of USD 3.58 billion by 2031, growing at a CAGR of 12.9% from 2024 to 2031. This growth is fueled by advancements in RNA-based research, rising incidences of chronic diseases, and the increasing adoption of miRNA-based diagnostics and therapeutics.

What is Driving the Growth of the MicroRNA Market?

Advancements in Biotechnology The continuous evolution of next-generation sequencing (NGS) and molecular biology technologies has significantly enhanced the detection, profiling, and understanding of miRNA. This progress has opened doors for new therapeutic and diagnostic applications.

Rising Incidence of Chronic and Genetic Diseases The increasing prevalence of chronic diseases such as cancer, cardiovascular diseases, and neurological disorders has led to a growing demand for miRNA-based diagnostics and therapeutics, as these molecules hold the potential to modulate gene expression effectively.

Emerging Role in Precision Medicine MicroRNA is becoming a vital component in precision medicine, offering solutions tailored to an individual’s genetic profile. This trend has driven research funding and investment in miRNA technologies.

Growing Focus on Early Diagnosis Early detection of diseases is crucial for effective treatment, and miRNA-based diagnostic tools are gaining popularity for their accuracy, reliability, and ability to identify diseases in their initial stages.

Request a Sample Report - https://www.skyquestt.com/sample-request/microrna-market

Market Segmentation: A Closer Look at Key Areas

By Application

Cancer Diagnostics & Therapeutics: The largest segment due to the rising prevalence of cancer and miRNA’s role in tumor suppression and oncogene regulation.

Neurological Disorders: Increasing use in diagnosing and treating neurodegenerative diseases like Alzheimer’s and Parkinson’s.

Cardiovascular Diseases: miRNA’s ability to regulate gene expression has made it essential in addressing heart diseases.

Others: Includes applications in metabolic disorders, infectious diseases, and stem cell research.

By Technology

Next-Generation Sequencing (NGS): Widely adopted for profiling and discovering novel miRNA biomarkers.

qRT-PCR: A cost-effective and reliable technology for miRNA quantification.

Microarray: Primarily used for miRNA expression profiling.

By End-User

Research Institutes: Significant demand for miRNA in academic and industrial research.

Pharmaceutical and Biotech Companies: Focused on developing miRNA-based drugs and therapies.

Clinical Diagnostics Laboratories: Increasing use of miRNA as diagnostic markers.

Speak to an Analyst for Customization - https://www.skyquestt.com/speak-with-analyst/microrna-market

Regional Insights: The Global Reach of the MicroRNA Market

North America North America dominates the market, driven by robust R&D funding, advanced healthcare infrastructure, and the growing adoption of miRNA technologies in clinical diagnostics and therapeutics.

Europe Europe represents a significant share of the market due to the rising prevalence of chronic diseases, government support for RNA research, and the strong presence of biotechnology companies in countries like Germany and the UK.

Asia-Pacific Asia-Pacific is the fastest-growing region, with countries like China, Japan, and India witnessing increasing investments in biotechnology and a growing focus on personalized medicine.

Latin America & the Middle East These regions are gradually emerging as potential markets, driven by increasing awareness of miRNA-based applications and improving healthcare infrastructure.

Make a Purchase Inquiry - https://www.skyquestt.com/buy-now/microrna-market

Key Market Players in the MicroRNA Landscape

The microRNA market is highly competitive, with numerous companies investing in R&D to develop innovative diagnostics and therapeutics. Major players include:

Thermo Fisher Scientific Inc.

Qiagen N.V.

Merck KGaA

Illumina, Inc.

Horizon Discovery Group plc

GeneCopoeia, Inc.

NanoString Technologies, Inc.

Abcam plc

New England Biolabs

Rosetta Genomics Ltd.

These companies are driving the market through strategic collaborations, partnerships, and the development of novel miRNA-based products.

Emerging Trends in the MicroRNA Market

Integration of Artificial Intelligence (AI) in miRNA Research AI and machine learning are being employed to analyze complex miRNA datasets, accelerating the discovery of novel biomarkers and therapeutic targets.

miRNA-Based Therapeutics The focus on RNA interference (RNAi) technologies is driving the development of miRNA-based drugs for treating diseases like cancer and genetic disorders.

Liquid Biopsies and miRNA Liquid biopsy technologies, which use miRNA as biomarkers, are revolutionizing non-invasive disease diagnostics, particularly in oncology.

Rising Collaborations Between Academia and Industry Academic institutions and biotech companies are forming partnerships to advance miRNA research and bring innovative products to market.

The Future of the MicroRNA Market

The global microRNA market holds immense potential, driven by its expanding applications across diagnostics and therapeutics. With increasing investments in research and the growing adoption of RNA-based technologies, the market is set to achieve remarkable growth in the coming years.Emerging regions, coupled with advancements in precision medicine and sustainable healthcare practices, will further drive innovation in this sector. Companies that prioritize R&D and focus on developing personalized solutions are well-positioned to lead the market in the future.

[shubhampawrainfinium]

A New Dimension of Biology: The Rise of Single Cell Multiomics

The global single cell multiomics market is experiencing significant growth, driven by advancements in biotechnology and the rising demand for precision medicine. According to the report, the market is projected to grow at a compound annual growth rate (CAGR) of approximately 18% during the forecast period of 2022-2028. In 2022, the global single cell multiomics market was valued at around USD 3.5 billion, and it is expected to reach nearly USD 9.5 billion by 2028.

What is Single Cell Multiomics?

Single cell multiomics is an advanced analytical approach that studies individual cells by combining multiple 'omics' platforms, such as genomics, transcriptomics, proteomics, and epigenomics. This method provides a comprehensive understanding of the cellular functions and the underlying molecular mechanisms. By analyzing a single cell's DNA, RNA, proteins, and epigenetic markers, researchers can uncover unique insights into cellular heterogeneity and disease mechanisms that are not possible with bulk cell analysis.

Get Sample pages of Report: https://www.infiniumglobalresearch.com/reports/sample-request/35323

Market Dynamics and Growth Drivers

Several factors are contributing to the rapid growth of the global single cell multiomics market:

Rising Demand for Precision Medicine: Precision medicine aims to tailor medical treatments to individual patients based on their genetic and molecular profile. Single cell multiomics plays a pivotal role in this approach by providing detailed insights into individual cells, enabling better understanding and treatment of complex diseases such as cancer, neurodegenerative disorders, and autoimmune diseases.

Technological Advancements: Advances in next-generation sequencing (NGS), mass spectrometry, and bioinformatics have made it easier and more cost-effective to conduct single cell multiomics studies. These innovations are driving adoption across academic and clinical research settings, allowing for more comprehensive analysis of cellular functions.

Growing Focus on Cancer Research: Cancer research is one of the primary applications of single cell multiomics, as it helps to decipher tumor heterogeneity, drug resistance, and tumor microenvironments at the single-cell level. The growing prevalence of cancer globally is fueling the demand for single cell multiomics in oncology research.

Increased Government and Private Funding: Governments and private organizations are investing heavily in genomics and precision medicine initiatives, providing funding and grants to support research in single cell analysis. These efforts are expected to boost market growth during the forecast period.

Regional Analysis

North America: North America holds the largest share of the global single cell multiomics market, primarily driven by the region’s advanced healthcare infrastructure, significant investment in precision medicine, and the presence of key market players. The United States, in particular, is a hub for genomics research, with major academic and research institutions adopting single cell technologies.

Europe: Europe is another prominent market for single cell multiomics, with countries like the U.K., Germany, and France at the forefront of multiomics research. The region’s robust research landscape, coupled with government initiatives supporting genomics research, is contributing to market growth.

Asia-Pacific: The Asia-Pacific region is expected to witness the fastest growth during the forecast period, driven by increasing investments in biotechnology and healthcare research in countries like China, Japan, and India. Growing awareness about precision medicine and improving healthcare infrastructure are also key factors driving market expansion in this region.

Rest of the World: While the adoption of single cell multiomics is still in its early stages in regions like Latin America and the Middle East & Africa, growing interest in genomics and personalized medicine is expected to create future growth opportunities.

Competitive Landscape

The global single cell multiomics market is highly competitive, with several key players actively contributing to advancements in the field. Major companies include:

10x Genomics: A leader in single cell sequencing technologies, offering solutions that enable comprehensive single cell multiomics analysis for research and clinical applications.

Illumina, Inc.: A major player in the genomics space, providing sequencing platforms and technologies that support single cell analysis and multiomics studies.

Fluidigm Corporation: Specializes in developing single cell proteomics and genomics platforms, helping researchers investigate cellular heterogeneity and molecular interactions.

Becton, Dickinson and Company (BD): Offers innovative solutions for single cell multiomics, including platforms for high-dimensional proteomics and transcriptomics.

QIAGEN: Known for its sample preparation and bioinformatics solutions, QIAGEN supports multiomics research by enabling comprehensive data analysis and integration.

Report Overview : https://www.infiniumglobalresearch.com/reports/global-single-cell-multiomics-market

Challenges and Opportunities

Despite its promising growth, the single cell multiomics market faces several challenges. High costs associated with single cell technologies and data analysis, as well as the complexity of multiomics data interpretation, may hinder widespread adoption, particularly in resource-constrained regions. Additionally, the integration of multiple 'omics' datasets and the lack of standardized protocols pose technical challenges.

However, there are substantial opportunities for growth. Continuous advancements in technology, decreasing costs of sequencing, and the growing adoption of artificial intelligence (AI) and machine learning (ML) for data analysis are expected to drive market expansion. Furthermore, as researchers uncover more insights into cellular heterogeneity, new applications of single cell multiomics in disease research, drug development, and personalized medicine are likely to emerge.

Conclusion

The global single cell multiomics market is poised for robust growth, with a projected CAGR of nearly 18% from 2022 to 2028. This market's expansion is fueled by increasing demand for precision medicine, advancements in biotechnology, and growing research applications in cancer and drug development. As the field of single cell multiomics continues to evolve, it holds the potential to revolutionize healthcare by enabling more accurate diagnostics, personalized treatments, and a deeper understanding of complex diseases.

[harshnews]

Acute Myeloid Testing Market Size, Share, Demand, Future Growth, Challenges and Competitive Analysis

"Global Acute Myeloid Testing Market - Industry Trends and Forecast to 2029

Global Acute Myeloid Testing Market, By Biomarker Type (Genetic AML Biomarker, Epigenetic AML Biomarker, Proteomic AML Biomarker), Product and Service (Services, Assay Kits), Technology (PCR, IHC, NGS, Cytogenetics, Others), End User (Clinical Laboratories, Hospitals, Academic and Research Institutes, Cancer Diagnostic Institutes, Others), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa) Industry Trends and Forecast to 2029.

Access Full 350 Pages PDF Report @

**Segments**

- **Type of Testing**: The acute myeloid testing market can be segmented based on the type of testing into molecular testing and immunophenotyping. Molecular testing involves the analysis of genetic mutations and abnormalities in the DNA of AML cells, aiding in the diagnosis and treatment of the disease. Immunophenotyping, on the other hand, enables the identification of specific proteins on the surface of AML cells, allowing for a more precise understanding of the disease progression.

- **End-User**: The market can also be segmented by end-users, including hospitals and diagnostic laboratories where acute myeloid testing is conducted. Hospitals often have dedicated oncology departments equipped with the necessary infrastructure for diagnosing and treating AML patients. Diagnostic laboratories, on the other hand, specialize in conducting various tests and analyses to assist healthcare professionals in identifying and managing AML cases.

- **Region**: Geographically, the acute myeloid testing market can be segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Each region has unique characteristics in terms of healthcare infrastructure, regulatory environment, and the prevalence of AML, which can influence the demand for testing services and technologies.

**Market Players**

- **Abbott Laboratories**: Abbott offers a range of diagnostic solutions for oncology, including tests for the detection and monitoring of acute myeloid leukemia. The company's commitment to innovation and quality has solidified its position as a key player in the acute myeloid testing market.

- **F. Hoffmann-La Roche Ltd**: Roche is a leading biotechnology company that provides cutting-edge diagnostic tools and methodologies for the detection and monitoring of various cancers, including AML. The company's strong focus on research and development has resulted in the introduction of advanced testing technologies for improved patient outcomes.

- **Sysmex Corporation**: Sysmex specializes in the development of automated hematology analyzers and diagnostic systems for blood-related disorders, including acute myeloidAbbott Laboratories, F. Hoffmann-La Roche Ltd, and Sysmex Corporation are prominent players in the acute myeloid testing market, each contributing significantly to the advancement of diagnostic solutions for AML. Abbott Laboratories, with its wide range of diagnostic solutions for oncology, has established itself as a key player in the market. The company's focus on innovation and quality has enabled it to provide reliable tests for the detection and monitoring of AML, catering to the diverse needs of healthcare providers and patients.

F. Hoffmann-La Roche Ltd, a leading biotechnology company, has made significant strides in the development of cutting-edge diagnostic tools for various cancers, including AML. Roche's strong emphasis on research and development has led to the introduction of advanced testing methodologies that enhance the accuracy and efficiency of AML diagnosis and monitoring. By leveraging its expertise in biotechnology, Roche continues to drive innovation in the acute myeloid testing market, ultimately improving patient outcomes and healthcare practices.

Sysmex Corporation's specialization in automated hematology analyzers and diagnostic systems for blood-related disorders, including AML, positions the company as a key player in the market. Sysmex's commitment to providing state-of-the-art solutions for AML testing underscores its dedication to advancing healthcare practices and improving patient care. By offering innovative diagnostic systems that deliver precise and reliable results, Sysmex plays a vital role in facilitating the early detection and effective management of AML cases, ultimately contributing to better treatment outcomes for patients.

As the acute myeloid testing market continues to evolve, these market players are expected to maintain their competitive edge through ongoing research and development efforts, strategic partnerships, and investments in new technologies. By staying at the forefront of innovation and continually adapting to the changing healthcare landscape, Abbott Laboratories, F. Hoffmann-La Roche Ltd, and Sysmex Corporation are well-positioned to meet the growing demand for advanced diagnostic solutions in the diagnosis and management of acute myeloid leukemia.**Global Acute Myeloid Testing Market Analysis**

- **Segments**

The global acute myeloid testing market can be segmented based on various factors such as the type of testing, end-users, and regions. When considering the type of testing, molecular testing and immunophenotyping play a crucial role in diagnosing and treating AML effectively. Molecular testing helps in analyzing genetic mutations, while immunophenotyping aids in identifying specific proteins on the surface of AML cells for a more precise understanding of the disease. In terms of end-users, hospitals and diagnostic laboratories are key players in conducting acute myeloid testing, as they have the necessary infrastructure and expertise to diagnose and manage AML cases. Geographically, the market can be segmented into regions like North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, each with its unique characteristics that influence the demand for testing services and technologies.

- **Market Players**

Abbott Laboratories, F. Hoffmann-La Roche Ltd, and Sysmex Corporation are prominent market players in the acute myeloid testing segment. Abbott's commitment to innovation and quality in providing diagnostic solutions for oncology has solidified its position in the market. Roche's focus on research and development has led to the introduction of advanced testing technologies for improved patient outcomes in detecting and monitoring AML. Sysmex's specialization in automated hematology analyzers and diagnostic systems for blood-related disorders positions it as a key player in the market,

TABLE OF CONTENTS

Part 01: Executive Summary

Part 02: Scope of the Report

Part 03: Research Methodology

Part 04: Acute Myeloid Testing Market Landscape

Part 05: Pipeline Analysis

Part 06: Market Sizing

Part 07: Five Forces Analysis

Part 08: Market Segmentation

Part 09: Customer Landscape

Part 10: Regional Landscape

Part 11: Decision Framework

Part 12: Drivers and Challenges

Part 13: Market Trends

Part 14: Vendor Landscape

Part 15: Vendor Analysis

Part 16: Appendix

How the Report Aids Your Business Discretion?

This section of this Market report highlights some of the most relevant factors and growth enablers that collectively ensure a high-end growth spurt

The report unravels details on pronounced share assessments across both country-wise as well as region-based segments

A leading synopsis of market share analysis of dynamic players inclusive of high-end industry veterans

New player entry analysis and their scope of new business models

The report includes strategic recommendations for new business veterans as well as established players seeking novel growth avenues

A detailed consultation services based on historical as well as current timelines to ensure feasible forecast predictions

A thorough evaluation and detailed study of various segments as well as sub-segments across regional and country-specific developments

Details on market estimations, market size, dimensions

A review of market competitors, their high-end product and service portfolios, dynamic trends, as well as technological advances that portray high end growth in this Market

The Report Can Answer the Following Questions:

Who are the global key players of Acute Myeloid Testing industry? How are their operating situation (capacity, production, price, cost, gross and revenue)?

What are the types and applications of Acute Myeloid Testing ? What is the market share of each type and application?

What are the upstream raw materials and manufacturing equipment of Acute Myeloid Testing ? What is the manufacturing process of Acute Myeloid Testing ?

Economic impact on Acute Myeloid Testing industry and development trend of Acute Myeloid Testing industry.

What are the key factors driving the global Acute Myeloid Testing industry?

What are the key market trends impacting the growth of the Acute Myeloid Testing market?

What are the Acute Myeloid Testing market challenges to market growth?

What are the Acute Myeloid Testing market opportunities and threats faced by the vendors in the global Acute Myeloid Testing market?

Browse Trending Reports:

12g Substrate Materials Market Cloud Application Programming Interface Api And Management Platforms And Middleware Market Abscisic Acid Aba Market Benign Mesonephroma Market Cancer Supportive Care Products Market Data Center Interconnect Market Potash Fertilizers Market Private Label Food And Beverage Market Relational Database Market Commercial Lighting Market Ethoxylates Market Eclinical Solutions Market Vaccines Market Spark Plug Market High Visibility Clothing Market Gas Turbine Services Market Dessert Mix Market Lipid Nutrition Market Barrier Films Flexible Electronics Market Nasal Polyposis Drugs Market

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact Us:

Data Bridge Market Research

US: +1 614 591 3140

UK: +44 845 154 9652

APAC : +653 1251 975

Email: corporatesales@databridgemarketresearch.com"

[healthcaremarketanalysis]

Blood Screening Market worth $3.4 billion by 2028

Blood Screening Market in terms of revenue was estimated to be worth $2.4 billion in 2023 and is poised to reach $3.4 billion by 2028, growing at a CAGR of 7.2% from 2023 to 2028 according to a new report by MarketsandMarkets™. Growth in this market is mainly driven by the growing requirement for donated blood, the rising number of blood donations around the world, and the ever-increasing infectious diseases. However, operational barriers and the high cost of Blood screening instruments is likely to hamper the growth of blood screening market.

Download an Illustrative overview:

Browse in-depth TOC on "Blood Screening Market"

189 - Tables

45 - Figures

220 – Pages

The Reagents & Kits segment is expected to account for the largest share in 2022.

Based on product, the blood screening market is segmented into reagents & kits, instruments, and software & services. Increase in demand and continuous use of the reagents and kits during blood transfusion processes, post blood donations is responsible for the large segment of this segment.

Nucleic Acid Test segment aimed the highest share during the forecast period

The blood screening market is segmented into nucleic acid tests (NAT), serology/immunoassay, rapid tests, western blot assays, and next-generation sequencing (NGS). In 2022, the nucleic acid test (NAT) segment accounted for the largest share of the blood screening market. From all the other technologies, NAT provides high precision, sensitivity and accuracy for blood screening and therefore, holds the largest share.

North America has the upper hand in the global Blood screening market

By regional segmentation, the blood screening market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East Africa. North America has the largest share and is continuing to dominate the blood screening market. The factors responsible for the large share of North America in this market are the increasing prevalence of infectious diseases, rising awareness in blood donations, and the growing healthcare system that is highly developed in the US and Canada.

Request Sample Pages:

Blood Screening Market Dynamics:

Drivers:

Increasing number of blood donations worldwide

Restraints:

Alternative technologies

Opportunities:

Emerging markets

Challenge:

High cost of blood screening technologies

Key Market Players:

The major players operating in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Grifols (Spain), Abbott Laboratories, Inc. (US), Bio-Rad Laboratories, Inc. (US), Danaher (Beckman Coulter, Inc.) (US), bioMérieux (France),  Hologic (US), Thermo Fisher Scientific, Inc. (US), Becton, Dickinson and Company (US), DiaSorin (Italy), Siemens Healthineers (Germany), QuidelOrtho Corporation (US), Merck KGaA (Germany), Revvity (Earlier known as PerkinElmer Inc.) (US), Bio-Techne Corporation (US), GFE (Germany), Trinity Biotech (Ireland), Mindray (China), Maccura Biotechnology Co., Ltd. (China), Immucor, Inc. (US), Cellabs (Australia), Abnova Corporation (Taiwan), Enzo Biochem, Inc. (US), J. Mitra & Co. Pvt. Ltd. (India) and Tulip Diagnostics (India).

Recent Developments:

In February 2023, Thermo Fisher Scientific Inc. (US) acquired TIB Molbiol (Germany), to expand its PCR test portfolio with a wide range of assays for infectious diseases.

In December 2021, Hologic, Inc. (US) launched Panther Trax for high-volume molecular testing.

In May 2021, Beckmann Coulter (US) launched SARS-CoV-2 IgG.

In September 2021, Roche Diagnostics (Switzerland) acquired TIB Molbiol Group (Germany). This acquisition will enhance Roche's broad portfolio of molecular diagnostics solutions with a wide range of assays for infectious diseases, such as identifying SARS-CoV-2 variants.

Inquiry Before Buying:

Blood Screening Market Advantages:

Early Disease Detection: Blood screening allows for the early detection of various diseases, including infections, cancers, and chronic conditions. Early diagnosis often leads to more effective treatment and improved patient outcomes.

Preventative Medicine: It enables preventative measures by identifying risk factors and potential health issues before they become serious. This proactive approach can lead to better health management and reduced healthcare costs.

Transfusion Safety: Blood screening is vital in ensuring the safety of blood transfusions. It screens for infectious agents like HIV, hepatitis, and syphilis, minimizing the risk of transmitting diseases through donated blood.

Population Health Management: Blood screening data can be analyzed on a population level, helping healthcare systems identify trends, allocate resources more effectively, and develop targeted public health interventions.

Personalized Medicine: Advances in blood screening techniques, such as genetic testing, allow for personalized treatment plans tailored to an individual's genetic makeup, improving the effectiveness of therapies and reducing adverse reactions.

Research and Drug Development: Blood screening plays a pivotal role in clinical trials and drug development, providing insights into treatment efficacy, patient response, and biomarker identification.

Point-of-Care Testing: Point-of-care blood screening devices enable rapid diagnostics in diverse settings, from clinics to remote areas, facilitating timely medical interventions and reducing the burden on healthcare facilities.

Healthcare Efficiency: Automating blood screening processes increases efficiency, reduces human error, and speeds up results, allowing healthcare providers to make quicker and more informed decisions.

Global Health: Blood screening contributes to global health efforts by identifying and controlling infectious diseases, making it an essential tool in disease surveillance and outbreak management.

Improved Quality of Life: Ultimately, the blood screening market's advantages contribute to an overall improvement in the quality of life for individuals and communities, promoting better health and well-being.

In summary, the blood screening market's advantages encompass early detection, preventative care, safety, personalized medicine, research, and healthcare efficiency, all of which have a profound impact on healthcare outcomes and public health.

Related Reports:

[wellnessweb]

Genomics Services Market Size: Investment and Opportunities

The Genomics Services Market size was valued at USD 32.5 billion in 2023 and is estimated to reach USD 111.03 billion in 2031, and grow at a compound annual growth rate approx. CAGR of 16.6% over the forecast period of 2024-2031.The genomics services market is experiencing robust growth, driven by advancements in next-generation sequencing (NGS), personalized medicine, and the increasing prevalence of genetic disorders. This market encompasses a wide range of services, including DNA sequencing, genotyping, gene expression profiling, and bioinformatics analysis. Companies are investing heavily in R&D to enhance the accuracy, speed, and affordability of genomic services, making them more accessible to both clinical and research settings. The integration of artificial intelligence and machine learning is further propelling the market, enabling more precise data interpretation and personalized therapeutic strategies. Additionally, the growing adoption of genomics in agricultural and forensic applications is expanding the market's scope, underscoring its pivotal role in shaping the future of healthcare and biological sciences.

Get Sample of This Report @ https://www.snsinsider.com/sample-request/2873

Market Scope & Overview

Market participants can use the research reports’ insight to better understand the Genomics Services Market and develop a profitable business expansion strategy. Production, manufacturing, sales, potential initiatives, and technological breakthroughs are all examined in the research. Product portfolios, investment goals, business and marketing strategy, and financial estimates are also included in the market study. The research also includes a SWOT analysis, a business description, and revenue figures for the leading international industry participants.

Market Segmentation Analysis

By Application & Deliverables

Functional Genomics

Epigenomics

Pathway Analysis

Biomarker Discovery

Others

By Deliverables

Products

Instruments/Systems/Software

Consumables & Reagents

Services

NGS-based Services

Core Genomics Services

Biomarker Translation Services

Computational Services

Others

By End users

Clinical Research

Academic & Government Institutes

Hospitals & Clinic

Pharmaceutical & Bio-Technology Companies

Other End Users

COVID-19 Impact Analysis

The supply chain, import and export limitations, regional government policies, and the sector's possible effects in light of the global COVID-19 outbreak were all evaluated in the analysis. Throughout the study, extensive Genomics Services Market research is carried out using a variety of research methods. The market research study investigates how a COVID-19 outbreak will affect the economy.

Regional Outlook

The research looks into noteworthy shifts in the Genomics Services Market on a global scale, with a particular emphasis on North America, Europe, Asia Pacific, Latin America, and the Middle East, and Africa. Powerful technologies, significant market trends, development patterns, growth drivers, restraints, challenges, threats, potential opportunities, standardization, value chain, regulatory environment, future forecasts, and critical methodology are all examined in the report's thorough analysis of the global market.

Competitive Analysis

The market research report covers production, manufacturing, sales, new projects, and technological advancements. The SWOT analysis of the Genomics Services Market is part of the market research study. The opinions of experts in the field and professionals are included in the report's conclusions. Sector specialists are attempting to determine which export/import policies promote the expansion of the global market.

Key Reasons to Buy this Genomics Services Market Report

A combination of primary and secondary sources were used to produce the report. Primary research techniques include questionnaires, interviews, and paying close attention to prominent members of the sector.

In light of the conflict involving Russia and Ukraine, the study paper emphasizes the need of understanding market conditions.

Conclusion

Key decision-makers, stakeholders, investors, suppliers, manufacturers, and participants who are interested in knowing more will find the Genomics Services Market report to be a priceless resource.

About Us

SNS Insider is a market research and insights firm that has won several awards and earned a solid reputation for service and strategy. We are a strategic partner who can assist you in reframing issues and generating answers to the trickiest business difficulties. For greater consumer insight and client experiences, we leverage the power of experience and people.

When you employ our services, you will collaborate with qualified and experienced staff. We believe it is crucial to collaborate with our clients to ensure that each project is customized to meet their demands. Nobody knows your customers or community better than you do. Therefore, our team needs to ask the correct questions that appeal to your audience in order to collect the best information.

Related Reports

Hospital Information System Market Analyasis

Image guided Biopsy Market Analyasis

Insulin Pump Market Analyasis

Medical X ray Market Analyasis

Nano Biotechnology Market Analyasis

[organicmarketresearch1]

United States Esoteric Testing Market Size, Share, Trends, Growth & Report 2032

United States Esoteric Testing market size was USD 7.37 billion in 2023 and the market is projected to touch USD 13.73 billion by 2032, at a CAGR of 7.16 % during the forecast period. Esoteric tests examine unique elements of health, revealing complex details that regular testing may miss. Esoteric testing is critical in identifying cancer, genetic problems, and infectious diseases, providing individualized insights for patient therapy. As the healthcare landscape evolves, so does demand for esoteric testing, which is driven by reasons such as increased awareness, technological developments, and the expanding occurrence of complicated health disorders. The dynamic nature of this market creates chances for innovation and expansion, encouraging collaborations among healthcare providers, laboratories, and technology companies to produce cutting-edge diagnostic solutions that improve patient outcomes and expand medical knowledge.

United States Esoteric Testing report scope and segmentation.

Report Attribute

Details

Base Year

2023

Forecast Years

2024–2032

Estimated Market Value (2023)

USD 7.37 Billion

Projected Market Value (2032)

USD 13.73 Billion

Segments Covered

By Material, By Type, By Technology, & By Region.

Forecast Units

Value (USD Million or Billion)

Quantitative Units

Revenue in USD million/billion and CAGR from 2024 to 2032.

Regions Covered

North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Countries Covered

U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Australia, Brazil, Argentina, GCC Countries, and South Africa, among others.

Download Free Sample Report

United States Esoteric Testing dynamics

Technological developments are constantly expanding testing capabilities, allowing the diagnosis of previously undetectable diseases and propelling market growth. Furthermore, the rising prevalence of chronic diseases and unusual conditions drives increasing demand for specialist tests, as healthcare providers seek precise diagnosis and individualized treatment choices. Furthermore, demographic trends such as aging populations contribute to market increase, as older people are more susceptible to complex illnesses that require esoteric testing.

Regulations and healthcare policies also have an impact on market dynamics. Changes in reimbursement policies, for example, affect the uptake and accessibility of esoteric testing, hence influencing market trends. Furthermore, strategic alliances and partnerships across healthcare organizations, labs, and technology providers promote innovation and market competitiveness. These agreements promote the development of novel testing procedures and improve the delivery of esoteric testing services, meeting changing healthcare needs.

Furthermore, consumer awareness and demand for preventive healthcare play a significant role in market dynamics. Growing awareness of the importance of early disease detection and proactive health management encourages individuals to seek esoteric testing services, driving market growth. Additionally, the integration of telemedicine and digital health solutions into the healthcare ecosystem expands access to esoteric testing, enabling remote consultations and sample collection, further shaping market dynamics.

Demand Report: https://organicmarketresearch.com/united-states-esoteric-testing-market

United States Esoteric Testing drivers

Technological Advancements

The United States Esoteric Testing Market is driven by ongoing advances in technology that allow for the development of more accurate and comprehensive testing procedures. Next-generation sequencing (NGS), molecular diagnostics, and advanced imaging techniques have improved the sensitivity and specificity of esoteric testing, allowing for the more precise diagnosis of rare diseases and complex circumstances. Furthermore, the automation and integration of artificial intelligence (AI) algorithms simplify testing processes, increasing productivity and cutting turnaround times. These technology improvements not only broaden the scope of esoteric testing but also make it more accessible and affordable, fuelling market growth and adoption among healthcare practitioners and consumers alike.

Rising Prevalence of Chronic Diseases

The rising prevalence of chronic diseases and rare disorders is a major driver of the United States Esoteric Testing Market. Cancer, cardiovascular disease, autoimmune disorders, and genetic disorders require specific diagnostic procedures beyond standard laboratory tests. Esoteric testing provides individualized solutions for early identification, illness monitoring, and personalized treatment options, which improve patient outcomes while lowering healthcare expenditures associated with late-stage therapies. Furthermore, advances in precision medicine and targeted therapeutics involve accurate molecular profiling and genetic testing, which increases demand for specialized testing services. As the burden of chronic diseases continues to rise, the market for esoteric testing is predicted to increase steadily, driven by the requirement for early diagnosis and optimized patient care techniques.

Restraints:

Cost Constraints

One of the major challenge to the United States Esoteric Testing Market is the high cost of specialist testing techniques. Esoteric tests can need sophisticated technologies, expert labor, and significant resources, resulting in increased costs for both healthcare professionals and patients. Furthermore, reimbursement procedures may not fully cover the cost of esoteric testing, creating financial hurdles for laboratories and limiting patient access to these services. Cost restrictions may prevent healthcare institutions from investing in advanced esoteric testing capabilities, limiting market growth and adoption, especially among underserved populations and resource-constrained settings.

Regulatory Challenges

Regulatory complexity and compliance requirements present major challenges for stakeholders in the esoteric testing market. The changing regulatory landscape, which includes licensure, accreditation, quality assurance, and data privacy rules, needs ongoing adaptation and adherence to strict standards. Obtaining regulatory permits for novel testing procedures and ensuring compliance with changing requirements takes time, resources, and expertise, which may hinder market entry and innovation. Furthermore, regulatory concerns about reimbursement rules and coding guidelines discourage investment in esoteric testing market, limiting industry expansion and innovation. To maintain compliance and develop market growth potential, it is necessary to engage with regulatory bodies proactively, communicate transparently, and implement strong quality management systems.

Opportunities:

Personalized Medicine and Precision Oncology

The paradigm change toward customized medicine and precision oncology provides enormous prospects for the US Esoteric Testing Market. With the increased emphasis on targeted medicines and molecular profiling, there is an increasing need for specialized tests that provide meaningful insights into patients’ genetic makeup, biomarker expression patterns, and treatment outcomes. Esoteric testing allows oncologists to adapt treatment regimens based on individual patients’ genomic profiles, improving therapeutic success while avoiding side effects. Furthermore, advances in liquid biopsy techniques provide non-invasive means for real-time monitoring of cancer progression and therapy response, hence improving patient care and clinical decision making. As precision medicine gains momentum, the market for esoteric testing is anticipated to expand, driven by the need for individualized diagnostic and therapeutic solutions across diverse disease indications.

Segment Overview

The United States Esoteric Testing Market includes a wide range of testing categories that cater to certain medical specializations and diagnostic needs. Infectious disorders Testing is the identification and characterization of pathogens such as bacteria, viruses, fungi, and parasites to aid in the diagnosis and treatment of infectious disorders like HIV/AIDS, hepatitis, and sexually transmitted infections. Endocrinology testing assesses hormone levels and glandular function, which is critical for detecting endocrine illnesses such as diabetes, thyroid dysfunction, and adrenal insufficiency. Oncology testing is essential for cancer diagnosis, prognosis, and therapy selection. It uses molecular profiling, genetic testing, and tumor biomarker analysis to guide tailored therapeutic interventions and track disease progression. Genetic Testing evaluates an individual’s genetic predisposition to inherited diseases, chromosomal abnormalities, and genetic mutations, facilitating early detection, risk assessment, and genetic counseling for conditions such as cystic fibrosis, Huntington’s disease, and hereditary cancers. Toxicology Testing involves the detection and quantification of toxic substances and drugs in biological specimens, essential for forensic investigations, workplace drug testing, and overdose management. Immunology Testing assesses the body’s immune response, including antibody production, autoimmune reactions, and immune system function, aiding in the diagnosis of autoimmune disorders, allergies, and immunodeficiency diseases. Neurology Testing encompasses diagnostic procedures for neurological disorders, including neurodegenerative diseases, neuromuscular disorders, and epilepsy, utilizing imaging studies, electrophysiological tests, and cerebrospinal fluid analysis to evaluate brain function and nerve integrity. Other esoteric testing segments encompass specialized diagnostic assays and procedures tailored to unique clinical indications and research applications, reflecting the breadth and complexity of the esoteric testing landscape.

The Market uses a wide range of advanced tools to offer precise and thorough diagnostic testing across a variety of medical specialties. Chemiluminescence Immunoassay quantifies analytes using light emission reactions, resulting in high sensitivity and a broad detection range ideal for infectious diseases, endocrinology, and oncology tests. The Enzyme-Linked Immunosorbent Assay (ELISA) detects and quantifies specific antigens or antibodies, making immunoassays for infectious diseases, autoimmune disorders, and allergy testing more efficient. Mass spectrometry allows for the identification and quantification of molecules based on their mass-to-charge ratio, facilitating high-throughput screening of proteins, metabolites, and medicines for toxicological, genetic, and neurology testing. Real-Time Polymerase Chain Reaction (PCR) amplifies and detects DNA sequences in real-time, offering rapid and sensitive molecular diagnostics for infectious diseases, genetic disorders, and oncology testing. Flow Cytometry analyzes and sorts cells based on their physical and chemical properties, enabling immunophenotyping, cell counting, and DNA analysis for immunology, oncology, and genetic testing. Radioimmunoassay (RIA) measures the concentration of antigens or antibodies using radioactive tracers, providing sensitive and specific assays for hormones, tumor markers, and therapeutic drug monitoring.

United States Esoteric Testing market competitive landscape

Major market players, including LabCorp, Quest Diagnostics, and Eurofins Scientific, dominate the industry due to their vast service portfolios, nationwide laboratory networks, and strong brand awareness. These industry giants use their scale, infrastructure, and technology skills to provide a wide range of esoteric testing services, including infectious illnesses, oncology, genetic testing, and specialist diagnostic tests. They also invest extensively in research and development to promote innovation, extend test options, and improve testing accuracy and efficiency. Along with established players, rising enterprises and start-ups contribute to market dynamics by offering novel testing technologies, diagnostic platforms, and specialized testing panels targeting specific clinical indications and research applications. Moreover, strategic collaborations, partnerships, and mergers and acquisitions are prevalent in the competitive landscape, enabling companies to enhance their market presence, geographic reach, and service offerings while fostering innovation and differentiation. Regional and local laboratories also play a significant role, catering to specific geographical markets and offering personalized services, rapid turnaround times, and specialized expertise in niche areas. Furthermore, academic medical centers and research institutions contribute to the competitive landscape through their cutting-edge research initiatives, clinical trials, and development of novel diagnostic assays, positioning themselves as key collaborators and innovators in the esoteric testing market.

Contact Us: Mob : +91 9319642100 Noida One Tower Sec 62 Noida 201301 Sales : sales@organicmarketresearch.com Website : https://www.organicmarketresearch.com

[healthcaremarketfmi]

NGS Sample Preparation Market Share, Top Operating Players, Recent Enhancements and Regional Analysis 2032

The global NGS sample preparation market is expected to be valued at $5441.1 million by 2032, up from $1321.8 million in 2022, and to grow at a 13.7% CAGR during the forecast period (2022-2032).

DNA contains the blueprints of life. Within its structures are the codes required for the assembly of proteins and non-coding RNA – these molecular machineries affect all the biological systems that create and maintain life. By understanding the sequence of DNA, researchers have been able to elucidate the structure and functisimultaneously enabled the sequencing of thousands to millions of DNA moleculesenabled the sequencing of thousands to millions of DNA molecules simultaneously.

This technology involves steps such as library preparation followed by clone amplification and cyclic array sequencing. This technology is used for applications including human whole genome sequencing (WGS), whole exome sequencing, targeted sequencing using panels of a few to thousands of genes, and expression profiling.

NGS Sample Preparation Market: Drivers and Restraints NSG samples are being used for the sequencing of genomes. These genomes are being used for the preparation of specialized medicines. Increasing prevalence of genetic disorders is driving the growth of this market. Increasing need for the personalized medicines and clinical diagnosis is driving the growth of NGS sample preparation market. Technological advancements in sample preparation procedures and kits to standardize and simplify steps are driving the growth of NGS sample preparation market.

NGS Sample Preparation Market: Overview NGS has revolutionized the genome sequencing market. NGS sample preparation market is expected to show significant growth over forecast period. Increasing need for personalized treatment is driving the growth of this market. Increase in the healthcare spending and improvement in the healthcare technology are the major factors for the growth of NGS sample preparation market. Increasing incidence of disease conditions like cancer and use of NGS for diagnostic purpose in cancer and management or treatment of disease the boosting the growth.

Aging population is also expected to drive the growth of NGS sample preparation market. Single molecule real time sequencing is expected to be fastest growing segment due to real time preparation of samples. Drug discovery and diagnostic application are expected be highest revenue generating and fastest growing NGS sample preparation segments. Biopharmaceutical companies are biggest user of NGS samples as these companies are focusing on development of new drugs.

For More Information : https://www.futuremarketinsights.com/reports/ngs-sample-preparation-market

NGS Sample Preparation Market: Region Wise Outlook

Geographically, the NGS sample preparation market can be segmented as North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding Japan, Japan and Middle East & Africa. North America is most attractive region for the NGS sample preparation market attributing to the presence of key biopharmaceutical players in this region and technological advancements. Followed by which is Europe and Japan. These markets are also growing significantly due to the focus of research institutes on development of new methods of NGS sample preparation and aging population. Asia Pacific excluding Japan is also expected to show significant growth in NGS sample preparation market due to improving healthcare infrastructure and increasing healthcare expenditure.

[research--blog]

Food Safety Testing Market Worth $29.6 Billion by 2027

 According to a new market research report titled “Food Safety Testing Market by Testing Type (Pathogens, Pesticides, GMO, and Toxins), Technology (Traditional and Rapid), and Food Tested (Meat, Poultry, & Seafood, Processed Food, Fruits & Vegetables, Dairy Products) – Global Forecast to 2027’, published by Meticulous Research®, the food safety testing market is expected to grow at a CAGR of 7.6% from 2020 to 2027 to reach $29.6 billion by 2027.

Download Free Sample Report Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=5111

Food testing is an essential part of the efficient production of harmless, valuable products. Today’s food industry demands inspection and testing to ensure good quality and protect public health. As adulteration is prevalent in the food industry, food testing requirement has a significant role. Food safety testing laboratories and food companies constantly conduct food safety tests to ensure that the product produced is edible using microbiological analysis. However, depending on the ingredients in the recipe, the laboratories recommend suitable testing for microbes.

The growth of the overall food safety testing market is backed by the rising incidence of food-borne illnesses, growing consumer awareness regarding the safety of food, implementation of stringent food safety regulations, and rising demand for convenience and packaged food products. Additionally, technological advancements for food safety testing methods provide significant growth opportunities for food safety testing manufacturers. However, the lack of infrastructure for food control, especially in developing nations, hinders this market’s growth to some extent. On the other hand, the lack of harmonization of food safety regulations poses a key challenge to the global food safety testing manufacturers.

The Impact of COVID-19 on the Food Safety Testing Market

The COVID-19 pandemic adversely hit many economies around the globe. As a measure to control the spread of this disease and avoid related severe consequences, governments across the globe announced partial or complete lockdown, which majorly impacted many manufacturing and service industries, including food safety testing.

There was an increasing consumer concern for processed food due to the outbreak of COVID-19 across different countries, leading to the increased demand for safe food. Due to the impact of COVID-19, in some areas, the food industry’s supply chain was disrupted or drastically changed with food business operators needing to adopt new business models, e.g. suppliers reorienting themselves to new markets. Food supply presented possible risks for infection, both environmentally (i.e. in food stores) or through contaminated foods/packaging. Apprehension pertaining to the safety of different types of food products is expected to increase the demand for tested food products in the coming years, driving the growth of the food safety testing market.

Speak to our Analysts to Understand the Impact of COVID-19 on Your Business: https://www.meticulousresearch.com/speak-to-analyst/cp_id=5111

To provide efficient analysis, Meticulous Research® has segmented overall food safety testing market based on testing type (pathogens {salmonella, campylobacter, E.coli, listeria, and others}, pesticides, GMO, toxins, and others), technology (traditional and rapid {PCR, DNA sequencing/NGS, immunoassay, chromatography, and spectroscopy}), food tested (meat, poultry, and seafood, processed food, fruits & vegetables, dairy products, cereals & grains, and others), and geography (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa).

Based on testing type, the food safety testing market is mainly segmented into pathogens, pesticides, Genetically Modified Organism (GMO), toxins, and others. The pathogens segment commanded the largest share of the overall food safety testing market in 2020. The large share of this segment is mainly attributed to the rising foodborne illness and food poisoning, implementation of stringent regulations pertaining to food safety, and growing consumer awareness regarding health. However, the GMO segment is expected to grow at the fastest CAGR during the forecast period.

Based on testing type, the pathogen food safety market is segmented into salmonella, campylobacter, E. coli, listeria, and others. The salmonella segment commanded the largest share of the overall pathogen food safety testing market in 2020. The large share of this segment is mainly attributed to the rise in prevalence of food products infection and increasing Salmonella bacteria infection in foods such as meat & poultry, dairy, processed food, cereal and grain, and fruits & vegetables.

“Exciting news! We are thrilled to announce an incredible opportunity for you!

 For a limited time only, we are delighted to offer an exclusive flat 30% discount on all our remarkable research reports. It's our way of showing appreciation for your continuous support and commitment to staying informed. This remarkable discount allows you to unlock a wealth of valuable insights and expert analysis at an unbeatable price. Whether you're a business professional, an academic researcher, or an avid learner, this offer is tailor-made to enhance your knowledge and empower your decision-making.”

Quick Buy – Food Safety Testing Market Research Report: https://www.meticulousresearch.com/Checkout/68175313

Based on technology, the food safety testing market is segmented into traditional and rapid technology. Rapid technology commanded the largest share of the overall food safety testing market in 2020. The large share of this segment is mainly due to factors such as multi-functional testing options in less time; flexible testing to end-user industry; increasing incidence of foodborne diseases, viruses, and other microbiological contaminants associated with inadequate storage conditions; and unsanitary food handling practices. Moreover, this segment is also expected to grow at the highest CAGR, mainly due to its ability to test a wide range of contaminants compared to traditional technology.

Based on type of food tested, the food safety testing market is mainly segmented into meat, poultry, and seafood, processed food, fruits & vegetables, dairy products, cereals & grains, and others. The meat, poultry, and seafood segment commanded the largest share of the overall food safety testing market in 2020, mainly attributed to growing meat production and consumption, increasing demand for seafood products such as shrimp, marlin, crabs, lobsters, tuna, etc., and increasing consumer awareness and foodborne pathogen outbreaks through meat, poultry, and seafood products. However, the fruits & vegetables segment is expected to witness significant growth.

Geographically, the North American region commanded the largest share of the global food safety testing market in 2020. However, the Asia-Pacific region is expected to grow at the highest CAGR during the forecast period. The rapid growth of this region is mainly attributed to the increasing demand for processed food products in emerging and developing countries such as India, China, Indonesia, & Thailand; the increasing number of poisoning outbreaks with consumption of contaminated meat; and the rise in cases of food degradation, such as contamination, pesticides, and artificial taste enhancer.

The key players operating in the global food safety testing market are SGS SA (Switzerland), Intertek Group plc (U.K.), Eurofins Scientific S.E. (Luxembourg), Thermo Fisher Scientific Inc. (U.S.), ALS Limited (Australia), Bureau Veritas SA (France), Merieux NutriSciences Corporation (U.S.), AsureQuality Limited (New Zealand), Microbac Laboratories, Inc. (U.S.), Romer Labs Division Holding GmbH (Austria), TÜV SÜD AG (Germany), NEOGEN Corporation (U.S.), FoodChain ID Group, Inc. (U.S.), R J Hill Laboratories Limited (New Zealand), Symbio Laboratories (Australia), and BIOTECON Diagnostics GmbH (Germany) among others.

To gain more insights into the market with a detailed table of content and figures, click here: https://www.meticulousresearch.com/product/food-safety-testing-market-5111

Scope of the report:

Food Safety Testing Market, by Testing Type              

Pathogens

Salmonella

Campylobacter

E. coli

Listeria

Others

Pesticides

Genetically Modified Organism (GMO)

Toxins

Others

Food Safety Testing Market, by Technology

Traditional

Rapid

Polymerase Chain Reaction (PCR)

DNA Sequencing/NGS

Immunoassay

Chromatography

Spectroscopy

Food Safety Testing Market, by Food Tested

Meat, Poultry, and Seafood

Processed Food

Fruits & Vegetables

Dairy Products

Cereals & Grains

Others

Food Safety Testing Market, by Geography

North America

U.S.

Canada

Europe

Germany

U.K.

France

Italy

Poland

Rest of Europe (RoE)

Asia-Pacific (APAC)

China

India

Japan

Australia

Rest of Asia-Pacific (RoAPAC)

Rest of World

Latin America

Middle East & Africa

Download Free Sample Report Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=5111

[ameymeti2001]

Pharmacogenomics Market Worth $13.16 billion by 2029

Pharmacogenomics Market Worth $13.16 billion by 2029

According to this latest publication from Meticulous Research®, the global pharmacogenomics market is projected to reach $13.16 billion by 2029, at a CAGR of 8.6% during the forecast period 2022–2029. The growth of this market is driven by growing therapeutic applications of pharmacogenomics biomarkers, increasing adoption of personalized medicine, rising geriatric population and chronic disease prevalence, and growing awareness of adverse drug reactions. However, the high cost of personalized medicine and a lack of reimbursement for genetic testing & precision medicine restrain the market growth. The increasing application of pharmacogenomics in neurological disorders and cancer and the development of new, more advanced, and accurate diagnostic tools are creating growth opportunities for this market. However, the low awareness of pharmacogenomics/personalized medicine among people and the knowledge gap about genetic testing and its benefits pose a challenge to this market.

Pharmacogenomics Market: Future Outlook

The global pharmacogenomics market is segmented by technology (polymerase chain reaction, DNA sequencing, electrophoresis, microarray, mass spectrometry, and other technologies), application (oncology, cardiology, neurological diseases, infectious diseases, and other applications), end user (hospitals, diagnostic laboratories, academic and research institutions and other end users), and geography. The study also evaluates industry competitors and analyzes the market at regional and country levels.

Based on technology, in 2022, the polymerase chain reaction segment is expected to account for the largest share of the pharmacogenomics market. The large market share of this segment is attributed to the high availability and usage of PCR across all end users. PCR is a cost-effective alternative to NGS and other technologies. Moreover, PCR is a highly sensitive technology and provides results with high accuracy and low sample volume requirement. These benefits of PCR allow for its high adoption across all end users.

Based on application, in 2022, the oncology segment is expected to account for the largest share of the pharmacogenomics Market. The large market share of this segment is attributed to the need for more targeted approaches in cancer therapy, the benefits offered by pharmacogenomics in cancer treatment, and the prevalence of cancer worldwide. The high prevalence of cancer globally calls for early detection and targeted cancer therapy to reduce mortality due to cancer. According to the International Agency for Research on Cancer, the estimated global number of new cancer cases in 2020 was around 19.3 million.

Based on end user, in 2022, the hospitals segment is expected to account for the largest share of the Pharmacogenomics Market. Hospitals are the primary preference for diagnosing and treating any chronic or infectious disease. There is a rising trend among hospitals to equip themselves with molecular diagnostics tools. Moreover, the presence of certified medical practitioners in hospitals contributes to the higher adoption of pharmacogenomics testing. These factors further boost the growth of the pharmacogenomics market.

This research report analyzes major geographies and provides a comprehensive analysis of North America (U.S., Canada), Europe (Germany, France, U.K., Italy, Spain, and the Rest of Europe), Asia-Pacific (Japan, China, India, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa. Based on geography, in 2022, North America is expected to account for the largest share of the global pharmacogenomics market, followed by Europe and Asia-Pacific. The high prevalence of chronic diseases and high awareness regarding risks of diseases in the future, technological advancements in molecular and sequencing technologies, and highly developed healthcare infrastructure support the large market share of this region.

The key players operating in the global pharmacogenomics Market are F. Hoffmann-La Roche Ltd (Switzerland), Abbott Laboratories (U.S.), Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Illumina, Inc. (U.S.), OPKO Health, Inc. (U.S.), Dynamic DNA Laboratories (U.S.), Admera Health (U.S.), Qiagen N.V. (Netherlands), and Myriad Genetics, Inc. (U.S.).

𝗗𝗼𝘄𝗻𝗹𝗼𝗮𝗱 𝗦𝗮𝗺𝗽𝗹𝗲 𝗥𝗲𝗽𝗼𝗿𝘁 @https://www.meticulousresearch.com/download-sample-report/cp_id=5366?utm_source=product&utm_medium=Social&utm_campaign=Product&utm_content=27-03-2023

Scope of the Report:

Pharmacogenomics Market, by Technology

Polymerase Chain Reaction

DNA Sequencing

Electrophoresis

Microarray

Mass Spectrometry

Other Technologies

(Note: Other Technologies include nucleic acid amplification technology, hybridization, and pyrosequencing)

Pharmacogenomics Market, by Application

Oncology

Cardiology

Neurologic Diseases

Infectious Diseases

Other Applications

(Note: Other Applications include pain management, psychiatry, forensic pathology, and basic research & drug development)

Pharmacogenomics Market, by End User

Hospitals

Diagnostic Laboratories

Academic & Research Institutions

Other End Users

(Other End Users include biopharmaceutical companies, clinical research organizations (CROS), and forensic laboratories)

Pharmacogenomics Market, by Geography

North America

U.S.

Canada

Europe

Germany

France

U.K.

Italy

Spain

Rest of Europe (RoE)

Asia-Pacific (APAC)

Japan

China

India

Rest of Asia-Pacific (RoAPAC)

Latin America

Brazil

Mexico

[global-research-report]

Empowering Healthcare Providers with Precision Blood Screening Tools

Blood Screening Industry Overview

The global blood screening market size is expected to reach USD 6.62 billion by 2030, registering a CAGR of 11.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is attributed to the increase in screening of donor and continuous technological advancement by the market players. Demand for blood screening tests is increasing continuously due to increasing donation, rising awareness about transfusion-transmitted diseases, and technological developments in the industry. Furthermore, governments of various countries are in process to mandates testing all donated blood for several viruses.

Thorough screening is necessary for all donated blood to ensure that recipients receive the safest products. As of 2015, such testing consists of screening for red cell antibodies, and the infectious diseases agents: HIV-1, HIV-2, hepatitis virus, West Nile Virus (WNV), Human T-Lymphotropic Virus (HTLV) T. Cruzi, and T. pallidum (syphilis). The result of all these assays must be negative for blood donation.

Gather more insights about the market drivers, restrains and growth of the Blood Screening Market

Technological developments increase the sensitivity and efficiency of the tests. For instance, in 2016, the U.S. FDA approved the Procleix Zika virus assay from Hologic, Inc. and Grifols to screen donated blood. Furthermore, the U.S. FDA approved next-generation sequencing (NGS) technology in 2013. The technology is cheaper and faster than previous DNA analysis methods.

Browse through Grand View Research's Clinical Diagnostics Industry Research Reports.

The global body fluid collection and diagnostics market size was estimated at USD 34.35 billion in 2024 and is projected to grow at a CAGR of 6.6% from 2025 to 2030. 

The global genetic testing market size was estimated at USD 11.71 billion in 2024 and is projected to grow at a CAGR of 22.5% from 2025 to 2030.

Blood Screening Market Segmentation

Grand View Research has segmented global blood screening market report based on technology, product, and region:

Blood Screening Technology Outlook (Revenue, USD Million, 2018 - 2030)

Nucleic Acid Amplification Test (NAT)

ELISA

Chemiluminescence Immunoassay (CLIA & EIA )

Next Generation Sequencing (NGS)

Western Blotting (WB)

Blood Screening Product Outlook (Revenue, USD Million, 2018 - 2030)

Reagent

Instrument

Blood Screening Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America

US

Canada

Mexico

Europe

UK

Germany

France

Italy

Spain

Norway

Denmark

Sweden

Asia Pacific

India

Japan

China

South Korea

Australia

Thailand

Latin America

Brazil

Argentina

Middle East and Africa (MEA)

Saudi Arabia

South Africa

UAE

Kuwait

Key Companies profiled:

Abbott

Danaher Corporation (Beckman Coulter)

Becton Dickinson and Company

Bio-Rad Laboratories, Inc.

Hoffman-La Roche Ltd.

Grifols, S.A.

Ortho-Clinical Diagnostics, Inc.

Siemens Healthcare GmbH

Thermo Fisher Scientific, Inc.

SOFINA s.a (Biomerieux)

Key Blood Screening Company Insights

Some of the key companies in the market include Bio-Rad Laboratories, Inc., Hoffman-La Roche Ltd., Grifols, S.A., and others. These companies adopt strategies such as strategic collaborations to enhance innovation, mergers, and acquisitions to expand capabilities, and new product launches to address evolving healthcare needs, ensuring competitiveness and a strong market presence.

Abbott manufactures specialized medical equipment that may utilize Blood Screening components for durability and lightweight properties. Beyond blood screening, Abbott operates in various segments, including laboratory diagnostics, cardiovascular devices, diabetes care, and nutrition products, thereby enhancing its portfolio and addressing diverse healthcare needs.

Bio-Rad Laboratories, Inc. develops diagnostic instruments that may incorporate Blood Screening materials for enhanced performance and reliability in relation to Blood Screening. The company also engages in other segments, such as quality control products, gene expression analysis, and protein purification, positioning itself as a leader in both research and clinical settings.

Recent Developments

In May 2023, Siemens Healthineers launched two new analyzers, the Atellica HEMA 570 and Atellica HEMA 580, designed for high-volume hematology testing, crucial for blood screening. These advanced devices can streamline the complete blood count (CBC) process, offering rapid results and improved workflow efficiency. With the ability to process up to 120 tests per hour, these analyzers can address the growing demand for timely diagnostics in critical care settings.

Order a free sample PDF of the Blood Screening Market Intelligence Study, published by Grand View Research.

[shubhampawrainfinium]

"Forensic Genomics: A Game-Changer for Justice or Just Another Ethical Dilemma?"

Introduction

The forensic genomics market is at the intersection of genomics and forensic science, providing advanced tools for criminal investigations, paternity testing, and human identification. This field is growing rapidly due to technological advancements, increasing crime rates, and the demand for accurate forensic tools.

Market Dynamics

Drivers

Technological Advancements: Innovations such as next-generation sequencing (NGS) and polymerase chain reaction (PCR) are enhancing the precision and speed of DNA analysis.

Rising Crime Rates: The global increase in crime is driving demand for advanced forensic tools that can offer conclusive evidence in criminal investigations.

Government and Legal Support: Increased funding and supportive regulations from governments and legal institutions are bolstering the adoption of forensic genomics technologies.

Restraints

High Costs: The high cost of advanced genomic technologies can be a barrier, particularly in developing regions.

Ethical Concerns: Issues related to privacy, data security, and potential misuse of genetic information pose challenges to the market's growth.

Sample pages of Report: https://www.infiniumglobalresearch.com/form/970?name=Sample

Market Segmentation

By Solution

Kits: Used for DNA extraction, quantification, and amplification, offering standardized processes for forensic labs.

Analyzers & Sequencers: Essential for high-throughput DNA analysis, enabling detailed genetic profiling.

Software: Critical for data analysis, storage, and interpretation, ensuring accuracy in forensic investigations.

Consumables: Reagents, primers, and other consumables are crucial components in forensic genomics workflows.

By Method

Capillary Electrophoresis (CE): A reliable traditional method for DNA profiling.

Next-Generation Sequencing (NGS): Revolutionizing forensic genomics with comprehensive, rapid DNA analysis.

PCR Amplification: Widely used for amplifying small quantities of DNA to generate sufficient material for analysis.

By Application

Criminal Testing: Predominantly used in criminal investigations to identify suspects and solve cases.

Paternity Testing: Increasingly popular for confirming biological relationships.

Familial Testing: Used for identifying missing persons and human remains, expanding the scope of the market.

Regional Insights

North America

United States: The largest market, driven by advanced forensic infrastructure and high demand for forensic services.

Canada: Significant market growth due to government support and adoption of advanced forensic technologies.

Europe

Germany, France, U.K.: Major markets due to strong forensic systems, technological adoption, and supportive government policies.

Asia-Pacific

China, India, Japan: Emerging markets with rapid adoption of forensic genomics technologies, driven by rising crime rates and government initiatives.

Rest of the World

Latin America, Middle East & Africa: Growing adoption of forensic genomics, though at a slower pace due to economic and technological barriers.

Competitive Landscape

Major Players

Key players in the forensic genomics market include Thermo Fisher Scientific, Qiagen, Promega Corporation, and Illumina. These companies are focused on product innovation, strategic partnerships, and expanding their global presence.

Strategic Developments

Partnerships and Collaborations: Companies are forming alliances to enhance their product offerings and market reach.

Product Launches: Continuous innovation in forensic genomics tools is driving market competition.

Mergers and Acquisitions: Companies are consolidating their market positions through strategic mergers and acquisitions.

Report Overview : https://www.infiniumglobalresearch.com/market-reports/global-forensic-genomics-market

Future Outlook

The global forensic genomics market is expected to continue its robust growth, driven by ongoing technological advancements and increasing applications in criminal justice, paternity testing, and human identification. Ethical considerations and cost barriers will remain challenges, but the market is likely to see significant innovation and expansion in the coming years.

Conclusion

The forensic genomics market is poised for substantial growth, offering advanced tools for more accurate and efficient forensic investigations. As technology continues to evolve, the market will play a crucial role in shaping the future of forensic science worldwide.

[reportcrux]

Asia Pacific Single-Cell Analysis Market Size, Trends and Forecast to 2027

Asia Pacific Single-Cell Analysis Market 2021 Report delivers in-depth data on market size, growth rate, share at country, region and segments level to frame strategic business plans and growth strategies for all business needs. The report is comprehensive blend of quantitative revenue data supported by qualitative data such as growth drivers, opportunities, market challenges, SWOT analysis, PEST analysis along with COVID-19 impact on the businesses across the world.

"Asia Pacific Single-Cell Analysis Market" report offers detailed analysis on specific developments in the market and key business strategies implemented by major market players to strengthen their businesses and market share. The report highlights company profiles, competitive landscape along with product benchmarking analysis for key market players.

Complete analysis on value (revenue),) and growth rate data are provided for years 2016 to 2027. Exhaustive key regional and country level trends and growth drivers are analysed to provide granular market analysis. Report demonstrates historic revenue and growth trends data for years 2016 to 2019 and forecast data for the years 2021 to 2027.

Request a Sample PDF of Report @ https://reportcrux.com/request-sample-report/Single-Cell-Analysis-Market

A thorough analysis on market effect factors, market risks, technological progress, consumer buying behaviour is covered along with value chain analysis, upstream and downstream market development trends and price and cost trends for product and raw materials.

Covid-19 impact analysis

Covid-19 impact analysis focuses on analysing pre- and post-pandemic growth trends, short term and long-term industry dynamics across major regions. Covid-19 recovery path analysis gives insights on the major strategies implemented by industries to respond and recover from the economic crisis due to Covid-19 pandemic. Also, SWOT analysis, PESTEL analysis and Porter's Five forces analysis is clear understanding of market growth influencing factors.

The report offers critical market information crucial for business decisions and strategy implementation based on current market trends and scope. The report also adds strategic inputs gained from key opinion leaders and business decision makers in the related industry.

Key Market Players:

Becton,     Dickinson and Company

Danaher     Corporation

Merck     Millipore

Qiagen     N.V.

Thermo     Fisher Scientific, Inc.

General     Electric Company

10x     Genomics

Promega     Corporation

Illumina,     Inc.

Bio-Rad     Laboratories, Inc.

Fluidigm     Corporation

Agilent     Technologies, Inc.

Nanostring     Technologies, Inc.

Tecan     Group Ltd.

Sartorius     AG

Luminex     Corporation

Takara     Bio Inc.

Fluxion     Biosciences

Menarini     Silicon Biosystems

Lumacyte

Others

The report is prepared by thorough primary and secondary research. Secondary data sources include company websites, magazines, press releases, SEC filings, various paid databases and others. Primary research involves interviews with key industry experts, KOLs, major vendors from both supply and demand side.

Are you Looking for Regional Insights / Report Customization? https://reportcrux.com/request-customization/Single-Cell-Analysis-Market

Asia Pacific Single-Cell Analysis market report is segmented as:

By Application

Research     Applications

Cancer

Immunology

Neurology

Stem     Cell

Other     Research Applications (Tissue Regeneration, Drug Discovery, and Research     on Aging)

Medical     Applications

Noninvasive     Prenatal Diagnosis

in     Vitro Fertilization

Circulating     Tumor Cell Detection

By Technique

Flow     Cytometry

Next-generation     Sequencing

Polymerase     Chain Reaction

Microscopy

Mass     Spectrometry

Other     Techniques (Fluorescence In Situ Hybridization (FISH), Capillary     Electrophoresis (CE), Single-Molecule Fluorescence In Situ Hybridization     (smFISH), and Micromanipulation)

By Cell Type

Human     Cells

Animal     Cells

Microbial     Cells

By Product

Consumables

Beads

Microplates

Reagents

Assay     Kits

Immunoassays

Cell-based     Assays

Other     Consumables (Culture Dishes, Flasks, Tubes, Cuvettes, Cryovials,     Filtration Apparatus, Petri Dishes, Inserts, and Discs)

Instruments

Flow     Cytometers

NGS     Systems

PCR     Instruments

Spectrophotometers

Microscopes

Cell     Counters

HCS     Systems

Microarrays

Other     Instruments (Laser Capture Microdissection (LCM) Systems,     Micromanipulation Devices, and Integrated Fluidic Circuits (IFCs))

By End User

Academic     & Research Laboratories

Biotechnology     & Pharmaceutical Companies

Hospitals     & Diagnostic Laboratories

Cell     Banks & IVF Centers

The regional scope covers value (revenue) data for below mentioned countries and regions:

North     America (U.S., Canada, Rest of North America)

Europe     (UK, Germany, France, Italy, Spain, Rest of Europe)

Asia     Pacific (China, Japan, India, Southeast Asia, Rest of Asia Pacific)

Latin     America (Brazil, Mexico, Rest of Latin America)

Middle     East and Africa (Saudi Arabia, UAE, South Africa, Rest of Middle East and     Africa)

Years considered in the report are:

Historic     Years: 2016-2019

Base     Year: 2019

Estimated     Year: 2020

Forecast     Year 2020 to 2027

Key Advantages to purchase Asia Pacific Single-Cell Analysis Market Report:

To     gain complete analysis on market potential, growth and trends data

To     analyse current competitive trends in the market and strategies used by     key players to strengthen their businesses & leading market position

Evaluate     major market challenges and risks and implement solutions or strategies to     mitigate the market risks

To     gain clear understanding of global market scope, potential, growth     influencing drivers, restraints and opportunities

To     perceive future market outlook and growth prospects for strategic business     decisions like geographic or product portfolio expansion

Besides     syndicate reports, we also offer customized research solutions and     consulting services for specific business needs

Key Highlights of Asia Pacific Single-Cell Analysis Market Report:

Granular     analysis of market size estimates in terms of value (revenue), and growth     rate at country and region level for each segment and sub-segment

Current     industry trends and developments shaping the market

Competitive     market share analysis for major market players, pricing and cost analysis     along with product benchmarking

Qualitative     analysis of growth driving factors, opportunities, restraints, market     challenges and risks or threats

Market     attractiveness analysis for each major segment

To     analyse the revenue pockets in the market for stakeholders or major     vendors by categorizing the specific high growth segments

  Browse Full Report Access here: https://reportcrux.com/summary/7145/Single-Cell-Analysis-Market

[healthcaremarketanalysis]

Liquid Biopsy Market worth $11.3 billion by 2029

Liquid Biopsy Market in terms of revenue was estimated to be worth $6.4 billion in 2024 and is poised to reach $11.3 billion by 2029, growing at a CAGR of 11.9% from 2024 to 2029 according to a new report by MarketsandMarkets™.

Liquid Biopsy Market Trends

Download an Illustrative overview:

Browse in-depth TOC on "Liquid Biopsy Market"

406 - Tables

56 - Figures

343 - Pages

North America is the largest regional market for liquid biopsy market.

The market for liquid biopsy has been divided into six key geographical regions, namely North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC countries. In 2023, North America held the predominant portion of the liquid biopsy market. The region boasts a well-developed healthcare infrastructure, including advanced diagnostic facilities, specialized oncology centers, and a skilled workforce. This infrastructure supports the integration of liquid biopsy into routine clinical practice, facilitating access for patients across various healthcare settings.

Liquid Biopsy Market Dynamics:

Drivers:

Rising incidence and prevalence of cancer

Cancer awareness initiatives undertaken by global health organizations

Benefits of liquid biopsy over traditional biopsy procedures

Restraints:

Lower sensitivity of certain liquid biopsy procedures

Opportunities:

Growing significance of companion diagnostics

Growth opportunities in emerging countries

Challenge:

Unclear reimbursement scenario

Key Market Players of Liquid Biopsy Industry:

The major players operating in this market are Natera, Inc. (US), QIAGEN (Netherlands), Myriad Genetics, Inc. (US), Illumina, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (US), Guardant Health (US), Bio-Rad Laboratories, Inc. (US), Exact Sciences Corporation (US), Sysmex Corporation (Japan), Biocept, In. (US), mdxhealth (US), Personalis, Inc. (US), NeoGenomics Laboratories (US), Epigenomics AG (Germany), ANGLE plc (UK), Menarini-Silicon Biosystems (Italy), Vortex Biosciences (US), Bio-Techne (US), MedGenome (US), Mesa Labs, Inc. (US), Laboratory Corporation of America Holdings (US), Freenome Holdings, Inc. (US), Strand (India), LungLife AI, Inc. (US), and Lucence Health Inc. (US).

The break-up of the profile of primary participants in the liquid biopsy market:

By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 – 30%

By Designation: C-level - 27%, D-level - 18%, and Others - 55%

By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6%, and Middle East & Africa- 4%

Get 10% Free Customization on this Report:

Recent Developments of Liquid Biopsy Industry:

In February 2024, Myriad Genetics, Inc. (US) entered into a definitive agreement to acquire select assets from Intermountain Health. These included assets from its Intermountain Precision Genomics (IPG) laboratory business, including the Precise Tumor Test, the Precise Liquid Test, and IPG's CLIA-certified laboratory.

In January 2024, Natera, Inc. (US) acquired certain assets relating to non-invasive prenatal and carrier screening business from Invitae (US).

In November 2023, Illumina, Inc. (US) launched its TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2.

In April 2023, QIAGEN (Netherlands) launched the QIAseq Targeted cfDNA Ultra Panels, enabling researchers studying cancer and other diseases to turn cell-free DNA (cfDNA) liquid-biopsy samples into libraries ready for NGS in less than eight hours.

In January 2022, Illumina, Inc. (US) partnered with Boehringer Ingelheim (Germany). This partnership was aimed to accelerate the development of therapy selection and precision medicines for patients with advanced cancer.

Liquid Biopsy Market - Key Benefits of Buying the Report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall liquid biopsy market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

Analysis of key drivers (Rising incidence and prevalence of cancer, cancer awareness initiatives undertaken by global health organizations, and increased benefits of liquid biopsy over traditional biopsy procedures), opportunities (Growing significance of companion diagnostics and growth opportunities in emerging countries), restraints (Lower sensitivity of certain liquid biopsy procedures), and challenges (Unclear reimbursement scenario) influencing the growth of the liquid biopsy market.

Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the liquid biopsy market.

Market Development: Comprehensive information about lucrative markets – the report analyses the liquid biopsy market across varied regions.

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the liquid biopsy market.

Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like Natera, Inc. (US), QIAGEN (Netherlands), Myriad Genetics, Inc. (US), Illumina, Inc. (US), and F. Hoffmann-La Roche Ltd (Switzerland).

About MarketsandMarkets™:

MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Contact:

Mr. Aashish Mehra

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: +1-888-600-6441

Email: sales@marketsandmarkets.com

Visit Our Website: https://www.marketsandmarkets.com/